FIG 7.

3p10LG9 has a moderate therapeutic effect against DENV-2 infection in primary human Langerhans cells. DENV-2-infected human skin DCs were transfected with 62 nM 3p10LG9, 3p10L, or G9neg at the indicated time points postinfection. Graphs showing the percentage of infected cells within each subpopulation of skin DCs (left) reflect staining with 4G2 antibody, as represented by the flow cytometry graphs on the right. The percentage of cells infected under each condition was normalized to the G9neg control per donor. (A) CD11c dermal DCs; (B) Langerhans cells; (C) CD14 dermal DCs. Each dot represents one donor. Statistical significance was determined using a one-way ANOVA with Dunnett’s multiple-comparison test (*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.005).